The Comparison of the Necessity of Repeat Myocardial Perfusion SPECT Studies Between Tc-99m Tetro and Tc-99m Mibi
| Status: | Completed |
|---|---|
| Conditions: | Angina, Peripheral Vascular Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/2/2016 |
| Start Date: | January 2010 |
| End Date: | February 2010 |
| Contact: | Danny A Basso, CNMT |
| Email: | dbasso@knology.net |
| Phone: | 7067243926 |
The Comparison of the Necessity of Repeat Myocardial Perfusion SPECT Studies Between Tc-99m Tetrofosmin and Tc-99m Sestamibi
Research Questions:
1. Is there a significant difference between the causal repeat rate of myocardial
perfusion studies for Tc99m tetrofosmin and Tc99m sestamibi?
2. Is there a significant difference in the causal repeat rate of myocardial perfusion
studies for Tc99m tetrofosmin and Tc99m sestamibi if an independent technologist
reviewer blinded to the radiopharmaceutical makes the decision to repeat the study?
3. Is there a significant difference in the quantitative diagnostic measures reported
between the original and the acceptable repeated studies?
1. Is there a significant difference between the causal repeat rate of myocardial
perfusion studies for Tc99m tetrofosmin and Tc99m sestamibi?
2. Is there a significant difference in the causal repeat rate of myocardial perfusion
studies for Tc99m tetrofosmin and Tc99m sestamibi if an independent technologist
reviewer blinded to the radiopharmaceutical makes the decision to repeat the study?
3. Is there a significant difference in the quantitative diagnostic measures reported
between the original and the acceptable repeated studies?
There are two commonly used Tc-99m based radiopharmaceuticals useful in the diagnosis and
localization of regions of reversible myocardial ischemia in the presence or absence of
infarction under exercise and rest conditions. One is Tc-99m tetrofosmin
(Tc-99m-1,2-bis[bis(2-ethoxyethyl) phosphino] ethane), the other is Tc-99m sestamibi
(Tc-99m- methoxyisobutylisonitrile). When performing a myocardial perfusion SPECT (MPS)
study, extracardiac subdiaphragmatic activity adjacent to the myocardium can cause artifacts
in the inferior wall and can be detrimental to the accuracy of the study1,2. Following
acquisition, MPS studies are routinely checked for potential imaging artifacts. When a
separation between the extracardiac activity cannot clearly be distinguished from the
myocardium, the study should be repeated. Repeating the SPECT study can affect the
efficiency of a lab as well as having a negative influence on patient comfort and overall
satisfaction. The goal of this study is to determine if there is a significant difference in
the number of studies that should be repeated between the two commonly used
radiopharmaceuticals.
localization of regions of reversible myocardial ischemia in the presence or absence of
infarction under exercise and rest conditions. One is Tc-99m tetrofosmin
(Tc-99m-1,2-bis[bis(2-ethoxyethyl) phosphino] ethane), the other is Tc-99m sestamibi
(Tc-99m- methoxyisobutylisonitrile). When performing a myocardial perfusion SPECT (MPS)
study, extracardiac subdiaphragmatic activity adjacent to the myocardium can cause artifacts
in the inferior wall and can be detrimental to the accuracy of the study1,2. Following
acquisition, MPS studies are routinely checked for potential imaging artifacts. When a
separation between the extracardiac activity cannot clearly be distinguished from the
myocardium, the study should be repeated. Repeating the SPECT study can affect the
efficiency of a lab as well as having a negative influence on patient comfort and overall
satisfaction. The goal of this study is to determine if there is a significant difference in
the number of studies that should be repeated between the two commonly used
radiopharmaceuticals.
Inclusion Criteria:
- Patients receiving sestamibi MPI study or tetrofosmin MPI study
Exclusion Criteria:
- Thallium or dual isotope MPI study
We found this trial at
1
site
Click here to add this to my saved trials
